A randomized, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis

  • Braude, Michael (Chief Investigator (CI))

Project: Research

Project Details

Project Description


StatusActive
Effective start/end date26/04/22 → 25/04/27

Keywords

  • phase 3 study
  • randomised control trial
  • treatment efficacy
  • treatment safety
  • liver fibrosis

Clinical Trial Phase

  • Phase III (a & b)